Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
IPO Year: 2017
Exchange: NASDAQ
Website: quanterix.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/1/2024 | $30.00 | Sector Outperform | Scotiabank |
| 9/25/2023 | $25.00 → $32.00 | Hold → Buy | Canaccord Genuity |
| 8/8/2023 | $30.00 | Market Perform → Outperform | SVB Securities |
| 5/23/2023 | $13.00 → $27.00 | Neutral → Buy | Goldman |
| 8/15/2022 | $40.00 → $12.00 | Buy → Hold | Canaccord Genuity |
| 8/9/2022 | $38.00 → $18.00 | Outperform → Market Perform | Cowen |
| 8/9/2022 | $35.00 → $15.00 | Outperform → Mkt Perform | SVB Leerink |
| 3/2/2022 | $85.00 → $60.00 | Overweight | JP Morgan |
| 3/2/2022 | $40.00 | Sell → Neutral | Goldman Sachs |
| 3/2/2022 | $70.00 → $50.00 | Outperform | SVB Leerink |
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
8-K/A - Quanterix Corp (0001503274) (Filer)
8-K - Quanterix Corp (0001503274) (Filer)
8-K - Quanterix Corp (0001503274) (Filer)
10-Q - Quanterix Corp (0001503274) (Filer)
8-K - Quanterix Corp (0001503274) (Filer)
8-K - Quanterix Corp (0001503274) (Filer)
SD - Quanterix Corp (0001503274) (Filer)
8-K - Quanterix Corp (0001503274) (Filer)
10-Q - Quanterix Corp (0001503274) (Filer)
8-K - Quanterix Corp (0001503274) (Filer)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
3 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
LucentADTM Complete improves on single biomarker tests, significantly reducing the intermediate zone, providing results for more patients Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ:QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer's Disease (AD) in a broader range of patients. Recent Alzheimer's Association criteria for diagnosing Alzheimer's recommend that plasma p-Tau 217 tests be designed with two cutoffs to confidently differentiate between patients with or without amyloid pathology, a hallmark of AD. However, this approach leaves an "intermediate zone" of uncertainty, requiring patients that fall into this zone
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, Inc. four years ago, where she serves as President and Chief Executive Officer. Under her leadership, Vigil raised more than $350 million and advanced its lead pipeline candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer's dis
Quanterix expands access to p-Tau 217 blood test kit using antibody technology licensed from Lilly Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it is making its Simoa® p-Tau 217 Planar Kit commercially available as part of the next phase of Alzheimer's Disease (AD) test development. The kit uses p-Tau 217 antibody technology licensed from Eli Lilly and Company and Quanterix's SP-X platform. In March 2022, Quanterix first announced its entry into license and collaboration agreements with Lilly, which specified the initial development of a test for the Eli Lilly Clinical D
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will take part in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 1:50 p.m. ET. The presentation will be available virtually and participants can register here. The presentation will be available for viewing following the conference on Quanterix's website here: ir.quanterix.com. To learn more about Quanterix, visit www.quanterix.com/company/. To learn more about Quanterix's Simoa® technology, visit: www.quanterix.com
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating officer from April 2021 to May 2023. While at Exact Sciences, he was responsible for finance, strategy and business development, helping to effectively scale the business, achieving high revenue growth during his tenure, and overseei
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024. "Our research business once again delivered strong performance in the second quarter, growing double digits," said Masoud Toloue, Chief Executive Officer of Quanterix. "Demand for Simoa sensitivity continues, as highlighted by a 35% increase in Accelerator service revenue compared to the corresponding prior year period, as customers are able to access our technology without impacting their capital expenditure budgets. For the balance of 2024, we expect to continue to execute against our strate
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will speak in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, at 3:00 p.m., ET. The presentation will be available virtually and participants can register using this link. The presentation will be available following the conference on Quanterix's website here. To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix's Simoa® technology, visit: https://www.quanterix.com/simoa-technology/. A
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 8, 2024 at 4:30 p.m. E.T., to discuss its second quarter 2024 financial results. Quanterix will issue a press release regarding the second quarter 2024 earnings prior to the conference call on Thursday, August 8, 2024 after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To pre-register for the conference call with a webcast link click here and for an audio only link click here to obtain your dial-in number and passcode. Interested investo
Quanterix improves on its best-in-class p-Tau 217 standalone test with new multi-marker approach reducing the number of patients receiving uncertain results Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today presented new data at the Alzheimer's Association International Conference (AAIC), supporting a novel multi-marker approach to test for Alzheimer's disease (AD). For the first time, new data show that applying a combination of AD-relevant biomarkers with p-Tau 217 significantly reduces the intermediate zone of a two-cutoff p-Tau 217 test, while preserving high accuracy above 90%. Recent Alzheimer's Associatio
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer, Masoud Toloue, and Chief Financial Officer, Vandana Sriram, will attend the Scotiabank Healthcare 1x1 Day on June 20, 2024. To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix's Simoa® technology, visit www.quanterix.com/simoa-technology. About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa ® technology has delivered the gol
SC 13G - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
SC 13G - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
SC 13G - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024. "Our research business once again delivered strong performance in the second quarter, growing double digits," said Masoud Toloue, Chief Executive Officer of Quanterix. "Demand for Simoa sensitivity continues, as highlighted by a 35% increase in Accelerator service revenue compared to the corresponding prior year period, as customers are able to access our technology without impacting their capital expenditure budgets. For the balance of 2024, we expect to continue to execute against our strate
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 8, 2024 at 4:30 p.m. E.T., to discuss its second quarter 2024 financial results. Quanterix will issue a press release regarding the second quarter 2024 earnings prior to the conference call on Thursday, August 8, 2024 after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To pre-register for the conference call with a webcast link click here and for an audio only link click here to obtain your dial-in number and passcode. Interested investo
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024. "Building on the foundation our team developed last year, Quanterix is entering a new innovation and product delivery phase," said Masoud Toloue, Chief Executive Officer of Quanterix. "We've announced the first of several new assays that could re-define the way Tau is measured from the brain versus peripheral sources. We will continue to lead in bringing novel biomarker detection solutions to market for the research community; developing tests to study and enable the early detection of neuro-pa
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Wednesday, May 8, 2024 at 8:30 a.m. E.T., to discuss its first quarter 2024 financial results. Quanterix will issue a press release regarding the first quarter 2024 earnings prior to the conference call on Tuesday, May 7, 2024 after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To pre-register for the conference call with a webcast link click here and for an audio only link click here to obtain your dial-in number and passcode. Interested investors can a
Quanterix Corporation (NASDAQ:QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both in the United States and abroad. Multiple patents—including U.S. Patent No. 11,275,092—are directed specifically to our novel approach to measuring Tau protein levels in biologic samples. Those interested in building Alzheimer's disea
Quanterix Corporation (NASDAQ:QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023, the deadline for which is February 29, 2024. The investor call will now be held on Thursday, February 29, 2024. Quanterix expects 2023 revenue, gross margin and cash usage to be in line with guidance provided on January 10, 2024. Quanterix expects to issue a press release regarding its fourth quarter 2023 and full year 2023 financial results
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud Toloue, the Company's President and Chief Executive Officer, and Vandana Sriram, the Company's Chief Financial Officer. Quanterix will issue a press release regarding the fourth quarter 2023 earnings and full year 2023 financial results prior to the conference call. The press release will be posted on the Quanterix website at https://www.quanterix
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended September 30, 2023. Third Quarter Financial Highlights Revenue was $31.3 million, an 18% increase from $26.6 million for the corresponding prior year period. GAAP gross margin was 56.8% as compared to 41.1% for the corresponding prior year period. Non-GAAP gross margin was 48.6% as compared to 34.9% for the corresponding prior year period. Net loss was $7.8 million as compared to $35.1 million for the corresponding prior year period. Net cash use was approximately $1.9 million. Cash, cash equivalent
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financial results for the third quarter 2023 after the market closes on Monday, November 6, 2023, and will host a webcast and conference call on Tuesday, November 7, 2023 at 8:30 a.m. E.T. Click here to pre-register for the conference call and obtain your dial-in number and passcode. Interested investors can also access the live webcast from the News & Events page within the Investors section of the Quanterix website at http://www.quanterix.com. An archived webcast replay will be available on the Company's website for one year. About
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended June 30, 2023. Second Quarter Financial Highlights Total revenue was $31.0 million versus prior year second quarter total revenue of $23.5 million, an increase of 32%. Second quarter revenue also increased 9% sequentially driven by increased Accelerator Lab and consumables revenue. Second quarter revenue includes a one-time benefit of approximately $1.5 million related to product and license agreements. GAAP gross margin was 61.7% compared to prior year second quarter GAAP gross margin of 37.1%. Non-GAAP
Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00
Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously
SVB Securities upgraded Quanterix from Market Perform to Outperform and set a new price target of $30.00
Goldman upgraded Quanterix from Neutral to Buy and set a new price target of $27.00 from $13.00 previously
Canaccord Genuity downgraded Quanterix from Buy to Hold and set a new price target of $12.00 from $40.00 previously
Cowen downgraded Quanterix from Outperform to Market Perform and set a new price target of $18.00 from $38.00 previously
SVB Leerink downgraded Quanterix from Outperform to Mkt Perform and set a new price target of $15.00 from $35.00 previously
JP Morgan reiterated coverage of Quanterix with a rating of Overweight and set a new price target of $60.00 from $85.00 previously
Goldman Sachs upgraded Quanterix from Sell to Neutral and set a new price target of $40.00
SVB Leerink reiterated coverage of Quanterix with a rating of Outperform and set a new price target of $50.00 from $70.00 previously
Goldman Sachs analyst Matthew Sykes maintains Quanterix (NASDAQ:QTRX) with a Buy and lowers the price target from $35 to $24.
Quanterix (NASDAQ:QTRX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.33) by 21.21 percent. This is a 62.5 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $32.066 million which beat the analyst consensus estimate of $31.620 million by 1.41 percent. This is a 12.69 percent increase over sales of $28.456 million the same period last year.
Canaccord Genuity analyst Kyle Mikson maintains Quanterix (NASDAQ:QTRX) with a Buy and lowers the price target from $32 to $25.
Those interested in building Alzheimer's disease (AD) testing infrastructure should contact Quanterix to discuss potential partnership opportunities, including avenues for receiving a non-exclusive license to U.S. Patent No. 11,275,092, to measure Tau protein using Quanterix's novel technique.
Scotiabank analyst Sung Nam maintains Quanterix (NASDAQ:QTRX) with a Sector Outperform and raises the price target from $30 to $32.
Quanterix Corporation (NASDAQ:QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer's Disease (AD). The FDA's Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need.p-Tau 217 has emerged as a top-performing biomarker for Alzheimer's pathology, with the NIA-AA criteria identifying p-Tau 217 as the only plasma biomarker appropria
2024 Full Year Business OutlookManagement expects full-year 2024 revenue to be in the range of $139 to $144 million. This guide is for our research-only business and does not include revenues from Diagnostics testing, which to date have not been material. GAAP gross margin percentage is expected to be in the range of 57-61%, and non-GAAP gross margin percentage is expected to be in the range of 51-55%. Additionally, the Company anticipates 2024 cash usage in the range of $25 to $30 million.For additional information on the non-GAAP financial measures included in this press release, please see "Use of Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Measures" bel
Quanterix (NASDAQ:QTRX) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.32) by 3.13 percent. This is a 34 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $31.55 million which beat the analyst consensus estimate of $29.84 million by 5.73 percent. This is a 22.17 percent increase over sales of $25.82 million the same period last year.
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. • NB Bancorp (NASDAQ:NBBK) is likely to report earnings for its Fiscal Year 2023. • Verona Pharma (NASDAQ:VRNA) is projected to report quarterly loss at $0.26 per share on revenue of $0. • iHuman (NYSE:IH) is estimated to report earnings for its fourth quarter. • argenx (NASDAQ:ARGX) is estimated to report quarterly loss at $1.71 per share on revenue of $364.75 million. • Titan Intl (NYSE:TWI) is expected to report quarterly earnings at $0.28 per share on revenue of $413.57 million. • Canadian Imperial Bank (NYSE:CM) is projected to repo
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, Inc. four years ago, where she serves as President and Chief Executive Officer. Under her leadership, Vigil raised more than $350 million and advanced its lead pipeline candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer's dis
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating officer from April 2021 to May 2023. While at Exact Sciences, he was responsible for finance, strategy and business development, helping to effectively scale the business, achieving high revenue growth during his tenure, and overseei
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it has appointed Vandana Sriram, CPA, as Chief Financial Officer (CFO), effective August 21, 2023. Sriram replaces Michael Doyle, who has served as the Company's CFO since July 2021. As previously announced, Mike will transition to the role of Executive Director, Finance, focusing on strategic growth programs until his retirement in March 2024. "Vandana is experienced in developing and executing strategic roadmaps and financial plans to foster growth opportunities," said Masoud Toloue, CEO at Quanterix. "The executive tea
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it has appointed Brian Blaser to its Board of Directors effective as of January 6, 2023. Mr. Blaser brings over 25 years of senior leadership experience in the in-vitro diagnostics industry, including 15 years at Abbott Laboratories where he was responsible for the company's global diagnostics organization, including its core laboratory, point of care, rapid diagnostics, and molecular diagnostics businesses. While at Abbott, he was responsible for the launch of the Alinity family of laboratory instruments and oversaw the acquisition of Alere that made
Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the appointment of experienced biotechnology executive, Dawn Mattoon, PhD, as Chief Operating Officer, effective today. In her nearly 20-year career, Dr. Mattoon has developed and commercialized a broad range of innovative proteomic and genomic technologies. Dr. Mattoon possesses a proven track record of delivering top and bottom-line growth as a leader in research and development, strategy, and general management for companies such as Invitrogen, Life Technologies, Thermo Fisher Scientific Inc. (NYSE:TMO), and Cell Signaling Technologies. Most recently, Dr.
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn, Senior Vice President and Chief Commercial Officer of Catalent Pharma Solutions (NYSE:CTLT), has been appointed to Quanterix' Board of Directors effective June 6, 2022. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She currently serves as Chief Commercial Officer of Catalent Pharma Solutions, a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies an
Doyle brings strong financial experience and track record to Quanterix Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has named Michael Doyle to the position of Chief Financial Officer (CFO) and Treasurer, effective July 12, 2021. Doyle replaces Shawn Stetson, who has served as the Company's Interim Chief Financial Officer and Treasurer. "Mike is a strong financial executive with deep experience serving as a public company CFO, and in light of our company's continued growth and opportunity to transform healthcare through our non-invasive early detection technology, we welcome
Toloue brings deep expertise and industry acumen to lead the Company's strategic expansion into diagnostics Quanterix Corporation (NASDAQ:QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced it has named Masoud Toloue to the position of President of Quanterix and Diagnostics, effective June 9, 2021. "We are excited to welcome Masoud to our team at such an important moment for Quanterix," said Kevin Hrusovsky, Chairman and Chief Executive Officer Quanterix. "We are making important strides in advancing our diagnostic capability and assays, given the NIH RADx funding, our COVID-19 Emergency Use Authorizations a
Pharmaceutical veteran adds deep expertise in commercial and corporate strategy Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the appointment of Laurie Olson to its Board of Directors, effective April 27, 2021. Olson is a seasoned pharmaceutical executive who brings more than three decades of experience in commercial and corporate strategy from Pfizer, Inc. to the Quanterix Board. She most recently served as executive vice president, strategy and commercial operations at Pfizer until 2018, where she led a team of approximately 2,000 people across 100 markets, with a scope including c